全文获取类型
收费全文 | 702776篇 |
免费 | 49983篇 |
国内免费 | 1283篇 |
专业分类
耳鼻咽喉 | 9174篇 |
儿科学 | 23210篇 |
妇产科学 | 17610篇 |
基础医学 | 109922篇 |
口腔科学 | 19971篇 |
临床医学 | 63413篇 |
内科学 | 133516篇 |
皮肤病学 | 16164篇 |
神经病学 | 49218篇 |
特种医学 | 25751篇 |
外国民族医学 | 76篇 |
外科学 | 104812篇 |
综合类 | 14785篇 |
现状与发展 | 2篇 |
一般理论 | 160篇 |
预防医学 | 51095篇 |
眼科学 | 16314篇 |
药学 | 53866篇 |
3篇 | |
中国医学 | 2295篇 |
肿瘤学 | 42685篇 |
出版年
2019年 | 5459篇 |
2018年 | 7891篇 |
2017年 | 6141篇 |
2016年 | 6853篇 |
2015年 | 7587篇 |
2014年 | 10314篇 |
2013年 | 15430篇 |
2012年 | 20561篇 |
2011年 | 21563篇 |
2010年 | 12761篇 |
2009年 | 11982篇 |
2008年 | 20068篇 |
2007年 | 21575篇 |
2006年 | 21969篇 |
2005年 | 20524篇 |
2004年 | 20055篇 |
2003年 | 18980篇 |
2002年 | 18498篇 |
2001年 | 36348篇 |
2000年 | 36889篇 |
1999年 | 30279篇 |
1998年 | 7548篇 |
1997年 | 6327篇 |
1996年 | 6602篇 |
1995年 | 6622篇 |
1994年 | 6087篇 |
1993年 | 5581篇 |
1992年 | 22989篇 |
1991年 | 22974篇 |
1990年 | 22370篇 |
1989年 | 22124篇 |
1988年 | 20066篇 |
1987年 | 19451篇 |
1986年 | 18508篇 |
1985年 | 17330篇 |
1984年 | 12714篇 |
1983年 | 10764篇 |
1982年 | 5908篇 |
1979年 | 11514篇 |
1978年 | 8132篇 |
1977年 | 6826篇 |
1976年 | 6583篇 |
1975年 | 7259篇 |
1974年 | 8492篇 |
1973年 | 8132篇 |
1972年 | 7654篇 |
1971年 | 7124篇 |
1970年 | 6873篇 |
1969年 | 6299篇 |
1968年 | 5780篇 |
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
31.
32.
33.
34.
Oga Emmanuel. A. Peters Erica. N. Mark Katrina Trocin Kathleen Coleman-Cowger Victoria. H. 《Maternal and child health journal》2019,23(2):250-257
Maternal and Child Health Journal - Background Prenatal substance use screening is recommended. The 4 P’s Plus screener includes questions on perceived problematic substance use in parents... 相似文献
35.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献36.
Julie A. Schmidt Georgina K. Fensom Sabina Rinaldi Augustin Scalbert Paul N. Appleby David Achaintre Audrey Gicquiau Marc J. Gunter Pietro Ferrari Rudolf Kaaks Tilman Kühn Heiner Boeing Antonia Trichopoulou Anna Karakatsani Eleni Peppa Domenico Palli Sabina Sieri Rosario Tumino Bas Bueno-de-Mesquita Antonio Agudo Maria-Jose Sánchez María-Dolores Chirlaque Eva Ardanaz Nerea Larrañaga Aurora Perez-Cornago Nada Assi Elio Riboli Konstantinos K. Tsilidis Timothy J. Key Ruth C. Travis 《International journal of cancer. Journal international du cancer》2020,146(3):720-730
Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case–control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD = 0.77, 95% confidence interval 0.66–0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD = 0.72, 0.57–0.90), or lysophosphatidylcholines (OR1SD = 0.81, 0.69–0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow-up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR1SD = 0.77, 0.61–0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer. 相似文献
37.
Ruby Del Risco Kollerud Hege S. Haugnes Bjørgulf Claussen Magne Thoresen Per Nafstad James M. Farnham Karl G. Blaasaas Øyvind Næss Lisa A. Cannon-Albright 《International journal of cancer. Journal international du cancer》2020,147(6):1604-1611
Similar family-based cancer and genealogy data from Norway and Utah allowed comparisons of the incidence of testicular cancer (TC), and exploration of the role of Scandinavian ancestry and family history of TC in TC risk. Our study utilizes data from the Utah Population Database and Norwegian Population Registers. All males born during 1951–2015 were followed for TC until the age of 29 years. A total of 1,974,287 and 832,836 males were born in Norway and Utah, respectively, of whom 2,686 individuals were diagnosed with TC in Norway and 531 in Utah. The incidence per year of TC in Norway (10.6) was twice that observed in Utah (5.1) for males born in the last period (1980–1984). The incidence rates of TC in Utah did not differ according to the presence or absence of Scandinavian ancestry (p = 0.669). Having a brother diagnosed with TC was a strong risk factor for TC among children born in Norway and Utah, with HR = 9.87 (95% CI 5.68–17.16) and 6.02 (95% CI 4.80–7.55), respectively; with even higher HR observed among the subset of children in Utah with Scandinavian ancestry (HR = 12.30, 95% CI 6.78–22.31). A clear difference in TC incidence among individuals born in Norway and descendants of Scandinavian people born in Utah was observed. These differences in TC rates point to the possibility of environmental influence. Family history of TC is a strong risk factor for developing TC in both populations. 相似文献
38.
39.
L. Piram T. Frédéric-Moreau R. Bellini F. Martin J. Miroir N. Saroul N. Pham Dang J. Biau M. Lapeyre 《Cancer radiothérapie》2019,23(3):272-269
Salivary glands tumours are uncommon tumours showing a large diversity of histological types. This article presents a synthesis of patterns and paths of invasion of parotid glands tumours in order to propose an approach of the delineation of primary tumour clinical target volumes and of the selection of lymph nodes target volumes. This article does not discuss treatment indications but defines clinical target volumes to treat if radiotherapy is indicated. Postoperative situation being the most frequent, the delineation of primary tumour clinical target volume is based on an anatomical approach. 相似文献